Adaptive Comfort Models Applied to Existing Dwellings in Mediterranean Climate Considering Global Warming

Comfort analysis of existing naturally ventilated buildings located in mild climates, such as the ones in the Mediterranean zones, offer room for a reduction in the present and future energy consumption. Regarding Spain, most of the present building stock was built before energy standards were mandatory, let alone considerations about global warming or adaptive comfort. In this context, this research aims at assessing adaptive thermal comfort of inhabitants of extant apartments building in the South of Spain per EN 15251:2007 and ASHRAE 55-2013. The case study is statistically representative housing built in 1973. On-site monitoring of comfort conditions and computer simulations for present conditions have been carried out, clarifying the degree of adaptive comfort at present time. After that, additional simulations for 2020, 2050, and 2080 are performed to check whether this dwelling will be able to provide comfort considering a change in climate conditions. As a result, the study concludes that levels of adaptive comfort can be considered satisfactory at present time in these dwellings, but not in the future, when discomfort associated with hot conditions will be recurrent. These results provide a hint to foresee how extant dwellings, and also dwellers, should adapt to a change in environmental conditions

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN